Ascentage Pharma Group International (6855.HK)
HKD 44.1
(6.78%)
HKD 44.1
(6.78%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 221.98 Million | 209.71 Million | 27.91 Million | 12.45 Million | 14.51 Million | 6.8 Million |
| Cost of Revenue | 30.54 Million | 21.99 Million | 3.32 Million | 1.96 Million | 2.09 Million | - |
| Gross Profit | 191.44 Million | 187.71 Million | 24.58 Million | 10.48 Million | 12.41 Million | 6.8 Million |
| Operating Expenses | 191.44 Million | 1.03 Billion | 847.2 Million | 684.89 Million | 1.5 Billion | 330.65 Million |
| Selling, General and Administrative Expenses | 376.46 Million | 328.01 Million | 191.26 Million | 130.34 Million | 161.64 Million | 61.49 Million |
| Research and Development Expenses | 706.97 Million | 743.1 Million | 766.49 Million | 564.57 Million | 463.88 Million | 249.56 Million |
| Other Expenses | - | -3.12 Million | -23.37 Million | -23.81 Million | -913.9 Million | -25.75 Million |
| Cost and Expenses | 1.11 Billion | 1.05 Billion | 850.53 Million | 686.86 Million | 1.5 Billion | 330.65 Million |
| Operating Income | -891.99 Million | -883.4 Million | -933.17 Million | -684.42 Million | -613.1 Million | -342.53 Million |
| Interest Expense | 96.05 Million | 52.78 Million | 16.73 Million | 6.25 Million | 4.27 Million | 36.91 Million |
| Income Tax Expense | -7.15 Million | 4.24 Million | 49.82 Million | 2.15 Million | 1.6 Million | -1.6 Million |
| Earnings before Tax | -932.86 Million | -887.17 Million | -832.24 Million | -675.44 Million | -1.48 Billion | -346.9 Million |
| Net Income | -925.63 Million | -882.92 Million | -782.42 Million | -677.6 Million | -1.48 Billion | -345.3 Million |
| Earnings Per Share Basic | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 |
| Earnings Per Share Diluted | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 |
| Weighted Average Shares Outstanding | 282.29 Million | 263.66 Million | 254.61 Million | 215.9 Million | 116.72 Million | 207.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 282.29 Million | 263.66 Million | 254.61 Million | 215.9 Million | 116.72 Million | 207.07 Million |
| Gross Margin | 0.86 | 0.90 | 0.88 | 0.84 | 0.86 | 1.00 |
| EBIT Margin | -3.35 | -3.99 | -32.82 | -53.61 | -41.08 | -47.61 |
| Profit Margin | -4.17 | -4.21 | -28.03 | -54.43 | -102.03 | -50.73 |
| EBITDA | -743.61 Million | -835.98 Million | -915.98 Million | -641.77 Million | -596.25 Million | -324.07 Million |
| Earnings Before Tax Margin | -4.02 | -4.21 | -33.43 | -54.97 | -42.25 | -50.32 |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 823.74 Million | 221.98 Million | 79.28 Million | 142.7 Million | 209.71 Million | 113.94 Million |
| Cost of Revenue | 15.05 Million | 30.54 Million | 12.38 Million | 18.15 Million | 21.99 Million | 16.97 Million |
| Gross Profit | 808.68 Million | 191.44 Million | 66.89 Million | 124.54 Million | 187.71 Million | 96.97 Million |
| Operating Expenses | 620.7 Million | 1.06 Billion | 598.96 Million | 477.46 Million | 1.03 Billion | 552.86 Million |
| Selling, General and Administrative Expenses | 176.62 Million | - | 201.8 Million | 174.65 Million | - | 174.33 Million |
| Research and Development Expenses | 444.07 Million | - | 397.15 Million | 309.81 Million | - | 401.69 Million |
| Other Expenses | - | -1.4 Million | - | - | -3.12 Million | - |
| Cost and Expenses | 635.76 Million | 1.09 Billion | 611.35 Million | 495.61 Million | 1.05 Billion | 569.84 Million |
| Operating Income | 187.98 Million | -838.93 Million | -532.06 Million | -359.92 Million | -883.4 Million | -479.05 Million |
| Interest Expense | - | 96.05 Million | - | - | 52.78 Million | - |
| Income Tax Expense | 69 Thousand | -7.15 Million | 9.89 Million | 2.74 Million | 4.24 Million | 8.73 Million |
| Earnings before Tax | 162.89 Million | -932.86 Million | -533.25 Million | -399.6 Million | -887.17 Million | -484.92 Million |
| Net Income | 163 Million | -925.63 Million | -523.28 Million | -402.35 Million | -882.92 Million | -476.19 Million |
| Earnings Per Share Basic | 0.55 | - | -1.80 | -1.47 | - | -1.81 |
| Earnings Per Share Diluted | 0.55 | - | -1.80 | -1.47 | - | -1.81 |
| Weighted Average Shares Outstanding | 296.36 Million | 274.55 Million | 290.04 Million | 274.55 Million | 263.66 Million | 263.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 296.02 Million | 274.55 Million | 290.04 Million | 274.55 Million | 263.66 Million | 263.66 Million |
| Gross Margin | 0.98 | 0.86 | 0.84 | 0.87 | 0.90 | 0.85 |
| EBIT Margin | 0.28 | - | -6.21 | -2.24 | - | -3.99 |
| Profit Margin | 0.20 | -4.17 | -6.60 | -2.82 | -4.21 | -4.18 |
| EBITDA | 229.58 Million | - | -492.67 Million | -320.14 Million | - | -454.91 Million |
| Earnings Before Tax Margin | 0.23 | -3.78 | -6.71 | -2.52 | -4.21 | -4.20 |
GW1
MSFT
1219
089980
HINDALCO
3924